Repurposing auranofin for the treatment of cutaneous staphylococcal infections

Highlights • Auranofin proves to be a superior topical agent than mupirocin and fusidic acid. • Auranofin reduces inflammatory cytokines in MRSA-infected skin lesions. • Auranofin exhibits potent antibiofilm activity.

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2016-03, Vol.47 (3), p.195-201
Main Authors: Thangamani, Shankar, Mohammad, Haroon, Abushahba, Mostafa F.N, Sobreira, Tiago J.P, Seleem, Mohamed N
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - therapeutic use
Auranofin
Auranofin - therapeutic use
Biofilms - drug effects
Cell Line
Chemokine CCL2 - biosynthesis
Drug Repositioning
Drug Resistance, Multiple, Bacterial
Drug Therapy, Combination
Female
Fusidic Acid - therapeutic use
Humans
Infectious Disease
Inflammatory cytokines
Interleukin-1beta - biosynthesis
Interleukin-6 - biosynthesis
Methicillin-Resistant Staphylococcus aureus - drug effects
Mice
Mice, Inbred BALB C
Microbial Sensitivity Tests
Multidrug resistance
Mupirocin - therapeutic use
Repurposing
Staphylococcal Skin Infections - drug therapy
Staphylococcal Skin Infections - microbiology
Staphylococcus epidermidis - drug effects
Topical antimicrobials
Tumor Necrosis Factor-alpha - biosynthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Auranofin proves to be a superior topical agent than mupirocin and fusidic acid. • Auranofin reduces inflammatory cytokines in MRSA-infected skin lesions. • Auranofin exhibits potent antibiofilm activity.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2015.12.016